Brain, Vol. 122, No. 12, 2279-2295,
December 1999
© 1999 Oxford University Press
Review article |
A quantitative analysis of oligodendrocytes in multiple sclerosis lesions
A study of 113 cases
.
1 Departments of Neurology, 2 Neuropathology and 3 Immunology, Mayo Clinic, Rochester, USA, 4 Institute of Neuropathology, Göttingen, Germany and 5 Institute of Neurology, Vienna, Austria
Correspondence to:
Dr Claudia Lucchinetti, Department of Neurology, Mayo Clinic, 200 First Street, SW, Rochester, Minnesota, USA E-mail: lucchinetti.claudia{at}mayo.edu
We studied quantitatively the fate of oligodendrocytes (OGs) during lesion formation in 395 lesion areas from biopsy and autopsy tissue of 113 multiple sclerosis cases. The density of OGs in multiple sclerosis lesions was variable at all stages of demyelinating activity, ranging from nearly complete loss to values exceeding those in the periplaque white matter (range 0–970 OGs/mm2). To determine whether there were distinct patterns of OG pathology in different patients, we restricted our analysis to the 56 cases in which the longitudinal extent of the lesion extended from periplaque white matter into the active demyelinating edge and inactive plaque centre. Two major groups of OG pathology were defined by the presence or absence of increased OGs within the lesion. In 70% (39 out of 56) of the cases, OGs were variably reduced during active stages of myelin destruction, but reappeared within inactive or remyelinating areas. In inactive areas, an increased number of OGs expressing proteolipid protein (PLP) mRNA compared with those expressing myelin oligodendrocyte glycoprotein (MOG) suggested these cells may have been derived from the progenitor pool. In the remaining 30% (17 out of 56) of the cases, extensive destruction of myelinating cells at active sites of demyelination was observed, but OGs were absent in inactive plaque areas without remyelination. In all lesions from a given patient the pattern of OG pathology remained consistent. A highly significant negative correlation was observed between number of macrophages in lesions and number of MOG- and PLP mRNA-labelled OGs (MOG: r = –0.32, P < 0.0000118; PLP mRNA: r = –0.23, P < 0.00238). OG density did not correlate with T-cell and plasma cell inflammation, or axonal loss. The profound heterogeneity in extent and topography of OG destruction in active demyelinating lesions suggests that in subsets of multiple sclerosis patients, myelin, mature OGs and possibly OG progenitors are differentially affected.
multiple sclerosis; oligodendrocytes; demyelination; pathology
CNPase = 2'3'-cyclic nucleotide 3'-phosphodiesterase; GFAP = glial fibrillary acidic protein; LFB = luxol fast blue myelin stain; MBP = myelin basic protein; MOG = myelin oligodendrocyte glycoprotein; OG = oligodendrocyte; PAS = periodic acid–Schiff reaction; PLP = proteolipid protein
* These authors contributed equally to the contents of this paper
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Wu, A. Chang, M. C. Smith, R. Won, X. Yin, S. M. Staugaitis, D. Agamanolis, G. J. Kidd, R. H. Miller, and B. D. Trapp {beta}4 Tubulin Identifies a Primitive Cell Source for Oligodendrocytes in the Mammalian Brain J. Neurosci., June 17, 2009; 29(24): 7649 - 7657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gaultier, X. Wu, N. Le Moan, S. Takimoto, G. Mukandala, K. Akassoglou, W. M. Campana, and S. L. Gonias Low-density lipoprotein receptor-related protein 1 is an essential receptor for myelin phagocytosis J. Cell Sci., April 15, 2009; 122(8): 1155 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Niklas, H Sebraoui, E Hess, A Wagner, and F Then Bergh Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency Multiple Sclerosis, January 1, 2009; 15(1): 68 - 74. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Lin, P. E. Kunkler, H. P. Harding, D. Ron, R. P. Kraig, and B. Popko Enhanced Integrated Stress Response Promotes Myelinating Oligodendrocyte Survival in Response to Interferon-{gamma} Am. J. Pathol., November 1, 2008; 173(5): 1508 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Diem, I. Demmer, S. Boretius, D. Merkler, B. Schmelting, S. K. Williams, M. B. Sattler, M. Bahr, T. Michaelis, J. Frahm, et al. Autoimmune Optic Neuritis in the Common Marmoset Monkey: Comparison of Visual Evoked Potentials with MRI and Histopathology Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3707 - 3714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kuhlmann, V. Miron, Q. Cuo, C. Wegner, J. Antel, and W. Bruck Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis Brain, July 1, 2008; 131(7): 1749 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Klistorner, S. Graham, C. Fraser, R. Garrick, T. Nguyen, M. Paine, J. O'Day, J. Grigg, H. Arvind, and F. A. Billson Electrophysiological Evidence for Heterogeneity of Lesions in Optic Neuritis Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4549 - 4556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Williams, G. Piaton, M.-S. Aigrot, A. Belhadi, M. Theaudin, F. Petermann, J.-L. Thomas, B. Zalc, and C. Lubetzki Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis? Brain, October 1, 2007; 130(10): 2554 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Khan Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology, May 29, 2007; 68(22_suppl_3): S64 - S71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lindquist, N. Bodammer, J. Kaufmann, F. Konig, H.-J. Heinze, W. Bruck, and M. Sailer Histopathology and serial, multimodal magnetic resonance imaging in a multiple sclerosis variant Multiple Sclerosis, May 1, 2007; 13(4): 471 - 482. [Abstract] [PDF]
|
|
|
|
|
|
P. Patrikios, C. Stadelmann, A. Kutzelnigg, H. Rauschka, M. Schmidbauer, H. Laursen, P. S. Sorensen, W. Bruck, C. Lucchinetti, and H. Lassmann Remyelination is extensive in a subset of multiple sclerosis patients Brain, December 1, 2006; 129(12): 3165 - 3172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Dugas, Y. C. Tai, T. P. Speed, J. Ngai, and B. A. Barres Functional Genomic Analysis of Oligodendrocyte Differentiation J. Neurosci., October 25, 2006; 26(43): 10967 - 10983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Merkler, B Schmelting, B Czeh, E Fuchs, C Stadelmann, and W Bruck Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions Multiple Sclerosis, August 1, 2006; 12(4): 369 - 374. [Abstract] [PDF]
|
|
|
|
|
|
W. Lin, A. Kemper, J. L. Dupree, H. P. Harding, D. Ron, and B. Popko Interferon-{gamma} inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress Brain, May 1, 2006; 129(5): 1306 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R P Lisak, J A Benjamins, B Bealmear, B Yao, S Land, L Nedelkoska, and D Skundric Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures Multiple Sclerosis, April 1, 2006; 12(2): 149 - 168. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. Frohman, M. K. Racke, and C. S. Raine Multiple sclerosis--the plaque and its pathogenesis. N. Engl. J. Med., March 2, 2006; 354(9): 942 - 955. [Full Text] [PDF]
|
|
|
|
 |
|
 S J Pittock, R L McClelland, S J Achenbach, F Konig, A Bitsch, W Bruck, H Lassmann, J E Parisi, B W Scheithauer, M Rodriguez, et al. Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1693 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Zajicek Diagnosis and disease modifying treatments in multiple sclerosis Postgrad. Med. J., September 1, 2005; 81(959): 556 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stadelmann, S. Ludwin, T. Tabira, A. Guseo, C. F. Lucchinetti, L. Leel-Ossy, A. T. Ordinario, W. Bruck, and H. Lassmann Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis Brain, May 1, 2005; 128(5): 979 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Biernacki, J. P. Antel, M. Blain, S. Narayanan, D. L. Arnold, and A. Prat Interferon Beta Promotes Nerve Growth Factor Secretion Early in the Course of Multiple Sclerosis Arch Neurol, April 1, 2005; 62(4): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Buss, K. Pech, D. Merkler, B. A. Kakulas, D. Martin, J. Schoenen, J. Noth, M. E. Schwab, and G. A. Brook Sequential loss of myelin proteins during Wallerian degeneration in the human spinal cord Brain, February 1, 2005; 128(2): 356 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F G Maggs and J Palace The pathogenesis of multiple sclerosis: is it really a primary inflammatory process? Multiple Sclerosis, June 1, 2004; 10(3): 326 - 329. [Abstract] [PDF]
|
|
|
|
|
|
C. Lucchinetti and W. Bruck The pathology of primary progressive multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(1_suppl): S23 - S30. [Abstract] [PDF]
|
|
|
|
|
|
J. L. Mason, A. Toews, J. D. Hostettler, P. Morell, K. Suzuki, J. E. Goldman, and G. K. Matsushima Oligodendrocytes and Progenitors Become Progressively Depleted within Chronically Demyelinated Lesions Am. J. Pathol., May 1, 2004; 164(5): 1673 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lucchinetti and W. Bruck The pathology of primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S23 - S30. [Abstract] [PDF]
|
|
|
|
|
|
O. Lily, J. Palace, and A. Vincent Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study Brain, February 1, 2004; 127(2): 269 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Frohman, D. S. Goodin, P. A. Calabresi, J. R. Corboy, P. K. Coyle, M. Filippi, J. A. Frank, S. L. Galetta, R. I. Grossman, K. Hawker, et al. The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, September 9, 2003; 61(5): 602 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Barkhof, W. Bruck, C. J. A. De Groot, E. Bergers, S. Hulshof, J. Geurts, C. H. Polman, and P. van der Valk Remyelinated Lesions in Multiple Sclerosis: Magnetic Resonance Image Appearance Arch Neurol, August 1, 2003; 60(8): 1073 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lassmann, M. Reindl, H. Rauschka, J. Berger, F. Aboul-Enein, T. Berger, A. Zurbriggen, A. Lutterotti, W. Bruck, J. R. Weber, et al. A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions Brain, June 1, 2003; 126(6): 1347 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Burks, B. G. Arnason, P. K. Coyle, C. C. Ford, A. Noronha, and K. W. Rammohan Issues and Practices in Multiple Sclerosis Neurorehabil Neural Repair, December 1, 2002; 16(4): 307 - 320. [Abstract] [PDF]
|
|
|
|
|
|
B. Stankoff, M.-S. Aigrot, F. Noel, A. Wattilliaux, B. Zalc, and C. Lubetzki Ciliary Neurotrophic Factor (CNTF) Enhances Myelin Formation: A Novel Role for CNTF and CNTF-Related Molecules J. Neurosci., November 1, 2002; 22(21): 9221 - 9227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Armstrong, T. Q. Le, E. E. Frost, R. C. Borke, and A. C. Vana Absence of Fibroblast Growth Factor 2 Promotes Oligodendroglial Repopulation of Demyelinated White Matter J. Neurosci., October 1, 2002; 22(19): 8574 - 8585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O'Connor Key issues in the diagnosis and treatment of multiple sclerosis: An overview Neurology, September 24, 2002; 59(90063): S1 - 33. [Full Text]
|
|
|
|
|
|
P. Charles, R. Reynolds, D. Seilhean, G. Rougon, M. S. Aigrot, A. Niezgoda, B. Zalc, and C. Lubetzki Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis? Brain, September 1, 2002; 125(9): 1972 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Frank, N. Richert, B. Lewis, C. Bash, T. Howard, R. Civil, R. Stone, J. Eaton, H. McFarland, and T. Leist A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients Multiple Sclerosis, September 1, 2002; 8(1_suppl): 24 - 29. [Abstract] [PDF]
|
|
|
|
|
|
D M Chari and W F Blakemore New insights into remyelination failure in multiple sclerosis: implications for glial cell transplantation Multiple Sclerosis, August 1, 2002; 8(4): 271 - 277. [Abstract] [PDF]
|
|
|
|
|
|
W Bruck, C Lucchinetti, and H Lassmann The pathology of primary progressive multiple sclerosis Multiple Sclerosis, April 1, 2002; 8(2): 93 - 97. [Abstract] [PDF]
|
|
|
|
|
|
X Montalban and A J Thompson Workshop on primary progressive multiple sclerosis: meeting summary Multiple Sclerosis, April 1, 2002; 8(2): 177 - 178. [PDF]
|
|
|
|
|
|
J A Frank, N Richert, B Lewis, C Bash, T Howard, R Civil, R Stone, J Eaton, H McFarland, and T Leist A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients Multiple Sclerosis, February 1, 2002; 8(1): 24 - 29. [Abstract] [PDF]
|
|
|
|
|
|
A. Chang, W. W. Tourtellotte, R. Rudick, and B. D. Trapp Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis N. Engl. J. Med., January 17, 2002; 346(3): 165 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Noseworthy, P. C. O'Brien, T. M. Petterson, J. Weis, L. Stevens, W. K. Peterson, D. Sneve, S. A. Cross, J. A. Leavitt, R. G. Auger, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis Neurology, June 12, 2001; 56(11): 1514 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. McTigue, P. Wei, and B. T. Stokes Proliferation of NG2-Positive Cells and Altered Oligodendrocyte Numbers in the Contused Rat Spinal Cord J. Neurosci., May 15, 2001; 21(10): 3392 - 3400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Mader, U. Seeger, R. Weissert, U. Klose, T. Naegele, A. Melms, and W. Grodd Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis Brain, May 1, 2001; 124(5): 953 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D J Werring, C A Clark, A G Droogan, G J Barker, D H Miller, and A J Thompson Water diffusion is elevated in widespread regions of normal-appearing white matter in multiple sclerosis and correlates with diffusion in focal lesions Multiple Sclerosis, April 1, 2001; 7(2): 83 - 89. [Abstract] [PDF]
|
|
|
|
|
|
N D Richert, J L Ostuni, C N Bash, T P Leist, H F McFarland, and J A Frank Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis Multiple Sclerosis, February 1, 2001; 7(1): 49 - 58. [Abstract] [PDF]
|
|
|
|
|
|
H. Lassmann The New Pathology of Multiple Sclerosis Multiple Sclerosis, December 1, 2000; 6(6): 409 - 410. [PDF]
|
|
|
|
|
|
S. Sathornsumetee, D. B. McGavern, D. R. Ure, and M. Rodriguez Quantitative Ultrastructural Analysis of a Single Spinal Cord Demyelinated Lesion Predicts Total Lesion Load, Axonal Loss, and Neurological Dysfunction in a Murine Model of Multiple Sclerosis Am. J. Pathol., October 1, 2000; 157(4): 1365 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker Multiple Sclerosis N. Engl. J. Med., September 28, 2000; 343(13): 938 - 952. [Full Text] [PDF]
|
|
|
|
 |
|
 C H Polman and B M J Uitdehaag Regular review: Drug treatment of multiple sclerosis BMJ, August 19, 2000; 321(7259): 490 - 494. [Full Text]
|
|
|
|
 |
|
 R. M. Ransohoff and C. Trebst Surprising Pleiotropy of Nerve Growth Factor in the Treatment of Experimental Autoimmune Encephalomyelitis J. Exp. Med., May 15, 2000; 191(10): 1625 - 1630. [Full Text] [PDF]
|
|